OncLive TV

Catherine Lai, MD, MPH, discusses ​the potential benefits of venetoclax in acute myeloid leukemia.

Priyanka Sharma, MD, discusses the rationale to combine veliparib with chemotherapy in triple-negative breast cancer.

Axel Grothey, MD, discusses biomarkers that can help to guide the treatment of metastatic colorectal cancer.

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.

Meletios A. Dimopoulos, MD, discusses the goal of the phase 3 ASPEN trial in Waldenström macroglobulinemia.

Naval G. Daver, MD, discusses the tolerability of magrolimab plus azacitidine in patients with acute myeloid leukemia and myelodysplastic syndrome.

Srdan Verstovsek, MD, PhD, discusses the phase 2 MANIFEST study, which examined CPI-0610 as an “add-on” to ruxolitinib in patients with myelofibrosis.

Jeffery Weitzel, MD, discusses the identification of ​Li-Fraumeni syndrome.

Georgina Long, BSc, PhD, MBBS, FRACP, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

Manish R. Patel, DO, discusses the safety profile of entrectinib in NTRK fusion–positive solid tumors.

César Serrano-García, MD, discusses the rationale for the phase 3 INVICTUS trial in patients with advanced gastrointestinal stromal tumors.

Daneng Li, MD, discusses the subgroup analysis of the phase 3 IMbrave150 trial in patients with unresectable hepatocellular carcinoma.

Mark D. Pegram, MD, discusses the results of the phase 2 DESTINY-Breast01 study examining fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer.

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of axitinib and pembrolizumab in advanced renal cell carcinoma.

Nathan Pennell, MD, PhD, discusses the evolution of targeted therapies in the field of non–small cell lung cancer.

Edward B. Garon, MD, discusses remaining questions with fam-trastuzumab deruxtecan-nxki in the field of lung cancer.

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Shubham Pant, MD, discusses targeting KRAS mutations in advanced or metastatic solid tumors.

Adam M. Brufsky, MD, PhD, discusses the treatment of early-stage, HER2-positive breast cancer.

William J. Gradishar, MD, discusses the benefit of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and stable brain metastases.

Narjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research. 

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Quoc-Dien Trinh, MD, discusses ​the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer. 

Lucy Gilbert, MD, MSc, discusses the rationale for evaluating mirvetuximab soravtansine in combination with bevacizumab in patients with platinum-agnostic ovarian cancer.

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.

Robert L. Ferris, MD, PhD, discusses the safety profile of transoral robotic surgical resection in oropharynx cancer.

Danja Sarink, PhD, discusses the importance of studying race and ethnicity in epithelial ovarian cancer research.

Bradley G. Somer, MD, discusses the impact of the phase 3 IMbrave150 trial on the treatment of patients with unresectable hepatocellular carcinoma.

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.